mTOR in podocyte function Is rapamycin good for diabetic nephropathy?

Comment on: Inoki K, et al. J Clin Invest 2011; 121:2181-2196 and Gödel M, et al. J Clin Invest 2011; 121:2197-2209

Saved in:
Bibliographic Details
Published inCell cycle (Georgetown, Tex.) Vol. 10; no. 20; pp. 3415 - 3416
Main Authors Lu, Min-Kan, Gong, Xing-Guo, Guan, Kun-Liang
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 15.10.2011
Landes Bioscience
Subjects
Animals
Binding
Biology
Bioscience
Calcium
Cancer
Cell
Cycle
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - metabolism
Landes
Mechanistic Target of Rapamycin Complex 1
Mice
Mice, Knockout
Monomeric GTP-Binding Proteins - metabolism
Multiprotein Complexes
Neuropeptides - metabolism
Organogenesis
Podocytes - metabolism
Podocytes - physiology
Proteins
Proteins - antagonists & inhibitors
Proteins - metabolism
Ras Homolog Enriched in Brain Protein
Signal Transduction - physiology
Sirolimus - pharmacology
Sirolimus - therapeutic use
TOR Serine-Threonine Kinases - metabolism
Tuberous Sclerosis Complex 1 Protein
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Online AccessGet full text

Cover

More Information
Summary:Comment on: Inoki K, et al. J Clin Invest 2011; 121:2181-2196 and Gödel M, et al. J Clin Invest 2011; 121:2197-2209
Bibliography:SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1538-4101
1551-4005
1551-4005
DOI:10.4161/cc.10.20.17686